At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, Chinese Academy of Medical Sciences and Peking Union Medical College scientists co-presented a carbonic anhydrase IX (CAIX)-targeting 68Ga/177Lu theranostic pair for clear cell renal cell carcinoma (ccRCC) and its preclinical evaluation.
Clear cell renal cell carcinoma (ccRCC) is still a clinical challenge due to its high metastasis rate at diagnosis and therapy resistance. It accounts for about 75%-80% of RCC cases. The magnesium transporter NIPA4 (NIPAL4) may influence tumor progression, but there is lack of knowledge on its prognostic value and role in ccRCC.
Multiple endogenous retroviruses (ERVs) in human DNA may be programmed to activate as cancer therapy. A recent study, led by scientists at the Dana-Farber Cancer Institute, expanded on a previously reported case of kidney cancer cure after hematopoietic stem cell transplantation attributed to the expression of an ERV driven by the hypoxia-inducible factor 2 (HIF2). The question was whether this finding might play out with different ERVs and different types of cancer through HIF.
Scientists from the University of Wisconsin-Madison have reported the discovery of novel carbonic anhydrase IX (CAIX) radioligands for molecular imaging in clear cell renal cell carcinoma (ccRCC).
Radiopharmaceutical company Telix Pharmaceuticals Ltd. received a U.S. FDA refusal to file letter for its BLA seeking approval of renal cancer imaging agent TLX250-CDx (89Zr-DFO-girentuximab) for clear cell renal cell carcinoma (ccRCC).
Researchers from Taipei Medical University have presented data from a study that assessed the role of KH-type splicing regulatory protein (KHSRP, also called KSRP) in clear cell renal cell carcinoma (ccRCC).
In a move to build up its dominance in the radiopharma market, Telix Pharmaceuticals Ltd. said it plans to acquire radioisotope production technology firm Artms Inc. and its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals.
Patients with polycystic kidney disease (PKD) are at high risk of developing end-stage renal disease, especially clear cell renal cell carcinoma (ccRCC). Since SET domain-containing 2 (SETD2) has been previously identified as an important tumor suppressor and an immunosuppressor in ccRCC, a recent study aimed to investigate the role of SETD2 in the progression of PKD into ccRCC.
Carbonic anhydrase IX (CAIX) is a transmembrane protein involved in cell proliferation and transformation that is expressed in clear-cell renal cell carcinoma (ccRCC), colorectal cancer (CRC), and other hypoxic tumor types, but has low expression in healthy tissues.
Previous studies revealed that cancer-restraining cancer-associated fibroblasts express Meflin as a marker in pancreatic cancer, and further research has shown that Meflin can also be a good predictive marker for immune checkpoint inhibitor (ICI) response in non-small-cell lung cancer.
